Please select the eligibility criteria that correspond to the clinical trial below.
Title: Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study
Brief Summary: The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.


Options:
A: Inclusion Criteria:

* Documented stable Coronary Artery Disease (stable angina, previous MI history, previous history of revascularization);
* Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception

Exclusion Criteria:

* History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or Coronary Artery Bypass Graft (CABG))
* History of liver or kidney disease
* Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma
* History of intolerance or allergy to Aspirin or clopidogrel
B: Inclusion Criteria:

* Peripheral arterial disease which requires intervention

Exclusion Criteria:

* Patient already on coumadin or clopidogrel
* Acute onset of PVD symptoms
* Patient requiring an operation
* Contraindication to aspirin and clopidogrel
C: Inclusion Criteria:

* Patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass.

Exclusion Criteria:

* Emergency surgery
* Valve surgery
* Redo CABG
* Left ventricle ejection fraction \< 30%
* Preoperative use of clopidogrel (with the exception of the current admission)
* Preoperative use of warfarin
* Allergy to aspirin or clopidogrel
* History of cerebrovascular accident
* History of severe liver disease
* Morbid obesity
* Current malignancy
D: Inclusion Criteria:

* Coronary artery disease including stable angina, unstable angina, acute non-ST elevation myocardial infarction and acute ST elevation myocardial infarction
* Age 20 years of older
* Patients with typical chest pain or evidences of myocardial ischemia (e.g., stable, unstable angina, silent ischemia and positive functional study or reversible changes in the electrocardiogram (ECG) consistent with ischemia
* Patients with signed informed consent
* Lesion and stent length for ACS and DM subgroup : Length of single lesion \< 24 mm and, Summation of total length of all inserted DES in 3 vessel \< 60 mm
* Lesion and stent length for ACS and DM subgroup : Length of single lesion \< 24 mm and, Summation of total length of all inserted DES in 3 vessel \< 60 mm
* Lesion and stent length for long lesion subgroup : Length of single stent per single lesion \> 28 mm and, Summation of total length of all inserted DES in 3 vessel ≤ 90 mm, Possible overlapping stent
* Lesion and stent length for short lesion subgroup : Length of single lesion \< 24 mm and, Summation of total length of all inserted DES in 3 vessel \< 60 mm
* Significant coronary artery stenosis (\>50% by visual estimate) considered for coronary revascularization with stent implantation
* Reference vessel diameter of 2.5 to 4.0 mm by operator assessment
* Lesion success (30% or less residual stenosis by visual assessment over the entire stent length, with TIMI-3 flow and no more than an NHLBI type B peri-stent dissection

Exclusion Criteria:

* Contraindication to anti-platelet agents \& bleeding history within prior 3 months
* Known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, limus related drug
* Prior history of the following presentations : Cerebral vascular accident (not including transient ischemic attack, Peripheral artery occlusive diseases, Thromboembolic disease, Stent thrombosis
* Severe hepatic dysfunction (3 times normal reference values)
* Significant renal dysfunction (Serum creatinine \> 2.0 mg/dl)
* Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
* Cardiogenic shock
* LVEF \< 40%
* Pregnant women or women with potential childbearing
* Life expectancy 3 year
* Overlapped DESs(only long lesion subgroup is possible overlapping)
* Left main disease requiring PCI
* Bifurcation lesion with 2-stent technique
* Target lesions with in-stent restenosis at the stented segment of DES or BMS
* Lesions with chronic total occlusion
* History of PCI with DES
* In-stent restenosis lesion

Answer: B